Paroxetine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Paroxetine: From SSRI Antidepressant Use to Ohdo Syndrome and Variants
One-Sentence Summary
Paroxetine (DrugBank DB00715) is generally classified as a selective serotonin reuptake inhibitor (SSRI), though the specific original indication is not documented in this evidence pack. The TxGNN model predicts a possible association with Ohdo syndrome and variants, a rare congenital chromatin-modification disorder, but this prediction is currently supported by no clinical trials, no literature, and no mechanistic evidence — only a model score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (paroxetine is generally classified as an SSRI antidepressant; no sourced indication text available) |
| Predicted New Indication | Ohdo syndrome and variants |
| TxGNN Prediction Score | 99.11% (rank 4433) |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for paroxetine is not available in this evidence pack. Based on general pharmacological classification, paroxetine is an SSRI, believed to act by inhibiting serotonin reuptake at the presynaptic neuron. However, without a documented original indication or confirmed MOA, this cannot be formally linked to the predicted new indication.
Ohdo syndrome and variants are a group of rare congenital disorders caused by mutations in genes such as KAT6B, MED12, and CUL4B, which are involved in chromatin modification and transcriptional regulation — a disease mechanism unrelated to serotonin signaling as currently understood. The repurposing rationale supplied with this candidate explicitly states that no direct biological connection could be established between paroxetine’s known pharmacology and the pathogenesis of Ohdo syndrome.
This prediction should be treated as a model-generated hypothesis only. The TxGNN score reflects a statistical association within the knowledge graph, not a validated pharmacological or clinical relationship. No independent evidence (trials, literature, or case reports) currently corroborates it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Paroxetine is not currently marketed in South Africa under this evidence pack, with 0 SAHPRA registrations on record. No product, dosage form, or approved-indication information is available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: This evidence pack flags a blocking data gap — SAHPRA/TFDA-equivalent warnings and contraindications are not yet available, which prevents completion of even a preliminary (Stage S1) safety assessment for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (Ohdo syndrome and variants) is supported only by a TxGNN model score, with no clinical trials, no literature, and no established mechanistic link — the repurposing rationale itself concludes there is no direct biological connection to paroxetine’s known pharmacology. In addition, a Blocking data gap on safety warnings/contraindications means this candidate cannot yet undergo initial safety screening.
To proceed, the following is needed:
- TFDA/SAHPRA-equivalent Professional Information (PI) — warnings, contraindications, and drug interaction data (Blocking gap)
- Confirmed mechanism of action (MOA) for paroxetine (High-priority gap)
- Documented original indication(s) for paroxetine, sourced from regulatory records
- Any preclinical or mechanistic studies linking SSRI pharmacology to chromatin-modification-related congenital disorders, if such evidence exists
- Given Ohdo syndrome’s rarity and genetic etiology, expert clinical genetics input before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.